COVID-19 — Worldwide/Unknown
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.
Methods: In this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate COVID-19, we randomly assigned 452 patients to receive a single intravenous
…
